

The logo for SynovAI features the word "SynovAI" in a black sans-serif font. A blue wavy line, resembling a chemical structure or a signal, is integrated into the letter "y".

SynovAI

*Accelerating the Future
of Synthetic Chemistry with
the Power of AI*

AI is revolutionizing chemical discovery — but synthesis is the bottleneck; not solving it will put billions in AI-driven R&D at risk

Chemical Industries with Synthetic Needs

Pharmaceuticals



Agricultural



Basic Chemicals



Consumer Products




- SynovAI solves synthetic bottlenecks with AI-powered retrosynthesis, providing exclusive value across chemical industries
- As the accessible chemical space grows, SynovAI's platform will grow with expanding market needs and broader applicability

SynovAI's retrosynthetic platform turns traditional inefficiencies into a streamlined, enriched, and collaborative synthetic design solution



Traditional Retrosynthesis Planning



Opportunities

Familiar Chemistry | Data backed alternative routes

Full Routes Generated

Up to a handful | Over a hundred

Collaboration

Slow ideation, drawing, data share, and feedback cycle | Auto-generated and linkable workspace

Multi-Criteria Optimization

Manually via many tools | Integrated in a single tool

Route Generation Efficiency

Hours-Days | Seconds-Minutes




SynovAI Retrosynthesis Planning



When a suboptimal route is selected, it can cause long term deficits and delays

SynovAI's platform combines key technical strengths to transform simple chemical inputs into numerous expert outputs in seconds



SynovAI's synthetically validated platform can turn years to weeks

Example of a KRAS G12C Inhibitor Intermediate (the alkyne)


Chemical Experts: >2 years R&D, 11-28% Yield

Org. Process Res. Dev. **2024**, 28, 78-91 doi.org/10.1021/acs.oprd.3c00363

Generation 1: 8 steps, 11% overall yield
Generation 2: 8 steps, 13% overall yield } Enzymatic to chemical resolution



Generation 3: 7 steps, 28% overall yield




Teams of chemical experts, >2 years of R&D



SynovAI + Chemical Experts: 2 weeks R&D, 33% Yield

Nat Commun **2024**, 15, 7818 https://doi.org/10.1038/s41467-024-52048-4

Chemical experts choosing from SynovAI generated novel synthetic pathways, unseen by current commercial software, **within two weeks**:



18 additional proposed routes have been synthetically validated


SynovAI can deliver where the competition does not, filling significant gaps in the competitive landscape

		 SynovAI	Reaxys	CAS SciFinder*	Synthia	Deep Forest
Critical Partnership Needs	Experimentally Validated	✓	✓	✓	✓	—
	Shareable Routes	✓	—	✓	✓	—
	Novel Pathways	✓	—	—	✓	✓
	Speed	✓	✓	—	—	—
Long Term Differentiators	Partner Customization	✓	—	—	—	—
	Efficient Scaling with Pathway Size	✓	—	—	—	—
	No Hand-Coded Rules	✓	—	—	—	—

* SciFinder has an existing strategic collaboration with molecule.one

SynovAI's chemical retrosynthesis solution provides significant economic opportunities across many industries in the U.S. and globally

U.S. Market Estimate





- The U.S. represents ~11% of total worldwide chemical production
- Current U.S. trade policy is likely to reshape global supply chains and on-shore chemical production, increasing the need for AI powered chemistry
- The larger international market provides ample opportunity to expand ex-U.S. over time as SynovAI gains recognition and expands its customer base
- Market opportunity is directly linked to the complexity of the underlying chemistry, largely dominated by pharmaceuticals, where increased upsides opportunities exist




SynovAI's platform delivers value across the whole R&D pipeline

As partner's needs change, the workflow remains the same



SynovAI's three-pronged business model creates customer value on a discrete and ongoing basis while generating new IP



SynovAI's technology has been deployed and is generating revenue with substantial long-term strategic growth potential

	Current State	Future State	
	Revenue Generating Live Platform	Personalized Partner Driven SAAS Platform	
Platform Status	• White glove partner projects • Partner acquisition demos • SaaS partnership deployment ready	• Finetuning customized SaaS solutions with partner data • Deployment of custom filters and partner supply chain integration • QoL and acceleration features	
Customer Focus	• Large pharmaceutical companies • Generic drug manufacturers • Other chemical companies	• Large chemical companies • Consumer chemical companies • Contract manufacturing and research organizations	
Process IP Pipeline	• ~35k Identified targets • ~13.1k Compounds evaluated	• Lab supporting model data enhancement, partner validation services, and asset process IP demonstration	
Outcomes	• Platform built to target early revenue generation • Real world use-case deployment • Traction and trust building • Select strategic customer targeting • Process IP potential development	• Recuring project and SaaS revenue expansion • Services revenue • Licensing revenue • Multiplicative customer reach • Enhanced model capabilities • Strategic customer acquisition • Process IP generation	
Customer Value	Accelerating Time to Market	Protecting New and Existing IP Value	Increasing Savings, Profitability, and Cashflow

SynovAI is inviting investors to join a \$5M Seed Round to enable delivery of multiple valuation inflection points in rapid succession



A \$5M investment will support execution of critical hiring, platform development, and laboratory build-out

SynovAI Use of Proceeds through 3Q27

(\$ thousands)

FTE Related Costs	3,250	65%
<i>Management</i>	900	-
<i>Technological Development (R&D)</i>	1,450	-
<i>Laboratory (R&D)</i>	650	-
<i>Sales</i>	250	-
Platform Development	450	9%
Overhead	350	7%
Professional Services	350	7%
Laboratory Capital Expenditures	550	11%
Other Capital Expenditures	50	1%
Total	5,000	

- Critical investments in platform capabilities will provide SynovAI's clients with superior and improving services while maintaining the company's competitive edge
- Build-out of laboratory service enables valuable end-to-end solutions, linking ideation to synthetically validated chemistry applications, and business sustainability through IP licensing
- SynovAI strives to operate with a light footprint with minimal investments in facilities and other non-platform assets

Use of proceeds covers execution of 18-month operating plan, including a tail-end cash burn of 6-months

The SynovAI team delivers leading innovation, technical expertise, and operational experience



Jessica Freeze, PhD

Co-Founder
President & Chief Executive Officer



Klas Holmlund, MBA, CFA

Co-Founder
Chief Operating Officer




Corey Jones, PhD

Co-Founder
Chief Scientific Officer



Victor Batista, PhD

Co-Founder
Board Member
Yale Kirkwood Professor of Chemistry



Journal of Chemical Theory and Computation

